{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:20:30Z","timestamp":1792635630140,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012326","name":"International Science and Technology Cooperation Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20220402068GH"],"award-info":[{"award-number":["20220402068GH"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["YDZJ202502CXJD079"],"award-info":[{"award-number":["YDZJ202502CXJD079"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.sleep.2025.106848","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:17:54Z","timestamp":1760145474000},"page":"106848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-5192","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoge","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2025.106848_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.sleep.2023.07.013","article-title":"Insomnia symptoms in adulthood. Prevalence and incidence over 25 years","volume":"109","author":"Klimt","year":"2023","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03163-9","article-title":"Exploring the mediating role of insomnia on the nexus between social media addiction and mental health among university students","volume":"15","author":"Jameel","year":"2025","journal-title":"Sci Rep"},{"issue":"Suppl 4","key":"10.1016\/j.sleep.2025.106848_bib3","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.37765\/ajmc.2020.43008","article-title":"Economic burden and managed care considerations for the treatment of insomnia","volume":"26","year":"2020","journal-title":"Am J Manag Care"},{"issue":"9","key":"10.1016\/j.sleep.2025.106848_bib4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult Pharm"},{"issue":"15","key":"10.1016\/j.sleep.2025.106848_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","article-title":"Suvorexant: first global approval","volume":"74","author":"Yang","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14196","article-title":"Early experience with the new DORA daridorexant in patients with insomnia disorder and comorbid mental disturbances: results of a naturalistic study with 3 months follow-up","volume":"33","author":"Palagini","year":"2024","journal-title":"J Sleep Res"},{"issue":"11","key":"10.1016\/j.sleep.2025.106848_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00228-022-03381-4","article-title":"Daridorexant for the treatment of insomnia disorder","volume":"78","author":"Jiang","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2025.106848_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.sleep.2021.09.005","article-title":"Efficacy and safety of zolpidem in the treatment of insomnia disorder for one month: a meta-analysis of a randomized controlled trial","volume":"87","author":"Xiang","year":"2021","journal-title":"Sleep Med"},{"issue":"7414","key":"10.1016\/j.sleep.2025.106848_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta\u2010analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jrsm.6","article-title":"Graphical displays for meta\u2010analysis: an overview with suggestions for practice","volume":"1","author":"Anzures\u2010Cabrera","year":"2010","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.sleep.2025.106848_bib12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/sim.4780070807","article-title":"A note on graphical presentation of estimated odds ratios from several clinical trials","volume":"7","author":"Galbraith","year":"1988","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.sleep.2025.106848_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/00401706.1988.10488400","article-title":"Graphical display of estimates having differing standard errors","volume":"30","author":"Galbraith","year":"1988","journal-title":"Technometrics"},{"issue":"4","key":"10.1016\/j.sleep.2025.106848_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib15","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta\u2010analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Systematic Rev"},{"key":"10.1016\/j.sleep.2025.106848_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sleep.2024.04.028","article-title":"Exploring the relationship between sleep disruptions and adolescent mental health","volume":"119","author":"Lei","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.106848_bib17","article-title":"Progress in GABAA receptor agonists for insomnia disorder","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib18","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/advances\/nmab060","article-title":"Dietary approaches to improve efficacy and control side effects of levodopa therapy in parkinson's disease: a systematic review","volume":"12","author":"Boelens Keun","year":"2021","journal-title":"Adv Nutr"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.sleep.2025.106848_bib20","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.bmcl.2013.06.057","article-title":"Selective orexin receptor antagonists","volume":"23","author":"Lebold","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.sleep.2025.106848_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107993","article-title":"The hypocretin (orexin) system: from a neural circuitry perspective","volume":"167","author":"Li","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.sleep.2025.106848_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149408","article-title":"The mechanism of different orexin\/hypocretin neuronal projections in wakefulness and sleep","volume":"1850","author":"Li","year":"2025","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.sleep.2025.106848_bib23","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/jnc.16195","article-title":"Orexin increases the neuronal excitability of several brain areas associated with maintaining of arousal","volume":"168","author":"Chen","year":"2024","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J Comp Neurol"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2025.106848_bib27","doi-asserted-by":"crossref","unstructured":"Zammit G, Dauvilliers Y, Pain S, Kinter DS, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 94(21):e2222-e2232.","DOI":"10.1212\/WNL.0000000000009475"},{"issue":"3","key":"10.1016\/j.sleep.2025.106848_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2025.106848_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-04072-4","article-title":"Efficacy and safety of lemborexant vs placebo in treating adults with insomnia disorder: a systematic review and meta-analysis of 1976 patients","author":"Alsaied","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"10.1016\/j.sleep.2025.106848_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"9","key":"10.1016\/j.sleep.2025.106848_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40266-024-01135-8","article-title":"Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials","volume":"41","author":"Gotfried","year":"2024","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.sleep.2025.106848_bib32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jcph.2192","article-title":"Exposure\u2013response analyses of polysomnography and subjective sleep efficacy end points from the phase 3 trials of lemborexant, a dual orexin receptor antagonist for the treatment of insomnia","volume":"63","author":"Lalovic","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single\u2010dose and multiple\u2010ascending\u2010dose phase 1 studies in healthy adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.sleep.2025.106848_bib34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.18553\/jmcp.2021.21011","article-title":"Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis","volume":"27","author":"McElroy","year":"2021","journal-title":"J Managed Care Specialty Pharm"},{"key":"10.1016\/j.sleep.2025.106848_bib35","article-title":"A phase 1 study of dimdazenil to evaluate the pharmacokinetics, food effect and safety in Chinese healthy subjects","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.sleep.2025.106848_bib36","first-page":"747","article-title":"Current status of research on the new sleep medication ditasin","volume":"24","author":"Zhai","year":"2024","journal-title":"Neurological Diseases Mental Health"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad271","article-title":"Efficacy and safety of dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study","volume":"47","author":"Li","year":"2024","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14035","article-title":"The european insomnia guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J Sleep Res"},{"issue":"8","key":"10.1016\/j.sleep.2025.106848_bib39","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0269881119855343","article-title":"British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update","volume":"33","author":"Wilson","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"34","key":"10.1016\/j.sleep.2025.106848_bib40","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.2174\/1381612821666150914121624","article-title":"GABA receptors: pharmacological potential and pitfalls","volume":"21","author":"Jembrek","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"12","key":"10.1016\/j.sleep.2025.106848_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0032-1327570","article-title":"Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers","volume":"62","author":"Wu","year":"2012","journal-title":"Arzneim Forsch"},{"issue":"12","key":"10.1016\/j.sleep.2025.106848_bib42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/17425255.2012.741588","article-title":"Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications","volume":"8","author":"Greenblatt","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib43","article-title":"Zolpidem: efficacy and side effects for insomnia","volume":"9","author":"Edinoff","year":"2021","journal-title":"Health Psychol Res"},{"key":"10.1016\/j.sleep.2025.106848_bib44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3389\/fphar.2018.01523","article-title":"Zolpidem activation of alpha 1-containing GABAA receptors selectively inhibits high frequency action potential firing of cortical neurons","volume":"9","author":"Neumann","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.sleep.2025.106848_bib45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinthera.2006.04.014","article-title":"Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia","volume":"28","author":"Najib","year":"2006","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","article-title":"The discovery of suvorexant, the first orexin receptor drug for insomnia","volume":"57","author":"Coleman","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","article-title":"International union of basic and clinical pharmacology CXIV: orexin receptor function, nomenclature and pharmacology","volume":"76","author":"Kukkonen","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"23","key":"10.1016\/j.sleep.2025.106848_bib48","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-Month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Boof","year":"2021","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleep.2025.106848_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13248","article-title":"Effect of the novel dual orexin receptor antagonist daridorexant on night\u2010time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease","volume":"30","author":"Boof","year":"2021","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.106848_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpsychires.2024.06.029","article-title":"Association between the use of orexin receptor antagonists and falls or fractures: a meta-analysis","volume":"176","author":"Pan","year":"2024","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.sleep.2025.106848_bib54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci Bull"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.9758\/cpn.2018.16.2.184","article-title":"Assessment of switching to suvorexant versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: a retrospective study","volume":"16","author":"Hatano","year":"2018","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.sleep.2025.106848_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222037","article-title":"Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts","volume":"2017","author":"Petrous","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.sleep.2025.106848_bib57","article-title":"Profile of suvorexant in the management of insomnia","volume":"6035","author":"Sutton","year":"2015","journal-title":"Drug Des Dev Ther"},{"issue":"1\u20132","key":"10.1016\/j.sleep.2025.106848_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant\u2014a novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib59","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1039856217734677","article-title":"Suvorexant: scientifically interesting, utility uncertain","volume":"25","author":"Keks","year":"2017","journal-title":"Australas Psychiatry"},{"issue":"11","key":"10.1016\/j.sleep.2025.106848_bib60","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14302","article-title":"Pharmacokinetics, safety, and efficacy of daridorexant in japanese subjects: results from phase 1 and 2 studies","volume":"34","author":"Uchiyama","year":"2025","journal-title":"J Sleep Res"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib62","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/cts.13079","article-title":"Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment","volume":"14","author":"Berger","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib63","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator","volume":"111","author":"Muehlan","year":"2022","journal-title":"Clin Pharma and Therapeutics"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12793\/tcp.2024.32.e5","article-title":"Emerging and upcoming therapies in insomnia","volume":"32","author":"Kim","year":"2024","journal-title":"Translational and Clinical Pharmacology"},{"key":"10.1016\/j.sleep.2025.106848_bib66","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2147\/NDT.S297504","article-title":"Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies","volume":"17","author":"Rosenberg","year":"2021","journal-title":"NDT"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PRA.0000000000000690","article-title":"Comparative pharmacology of the 3 marketed dual orexin antagonists\u2014daridorexant, lemborexant, and suvorexant\u2014part 2. Principal drug metabolizing enzyme, drug-drug interactions, and effects of liver and renal impairment on metabolism","volume":"29","author":"Preskorn","year":"2023","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cpdd.915","article-title":"Evaluation of the CYP3A and CYP2B6 drug\u2010drug interaction potential of lemborexant","volume":"10","author":"Landry","year":"2021","journal-title":"Clinical Pharm in Drug Dev"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib69","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed-sequence trials in healthy subjects","volume":"39","author":"Wrishko","year":"2019","journal-title":"Clin Drug Invest"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","article-title":"Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies","volume":"75","author":"Boof","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.734","article-title":"Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant","volume":"9","author":"Landry","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib72","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40265-024-02020-9","article-title":"Dimdazenil: first approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.sleep.2025.106848_bib73","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10072-024-07872-3","article-title":"Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis","volume":"46","author":"Ran","year":"2025","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1016\/j.sleep.2025.106848_bib74","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4140\/TCP.n.2020.549","article-title":"Z-drugs and falls: a focused review of the literature","volume":"35","author":"Ryba","year":"2020","journal-title":"The Senior care pharmacist"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40268-013-0019-3","article-title":"Risk of falling and hypnotic drugs: retrospective study of inpatients","volume":"13","author":"Obayashi","year":"2013","journal-title":"Drugs R&D"},{"issue":"5","key":"10.1016\/j.sleep.2025.106848_bib76","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2125.2010.03613.x","article-title":"Medication use as a risk factor for inpatient falls in an acute care hospital: a case\u2010crossover study","volume":"69","author":"Shuto","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jhm.1985","article-title":"Zolpidem is independently associated with increased risk of inpatient falls","volume":"8","author":"Kolla","year":"2013","journal-title":"J Hosp Med"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2318-14-121","article-title":"Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics","volume":"14","author":"Nurminen","year":"2014","journal-title":"BMC Geriatr"},{"issue":"7","key":"10.1016\/j.sleep.2025.106848_bib79","first-page":"S38","article-title":"Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines","volume":"24","author":"Baranchuk","year":"2008","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.sleep.2025.106848_bib80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.nrleng.2018.08.004","article-title":"Melatonin in sleep disorders","volume":"37","author":"Poza","year":"2022","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"6","key":"10.1016\/j.sleep.2025.106848_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J Sleep Res"},{"issue":"2","key":"10.1016\/j.sleep.2025.106848_bib82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.sleep.2025.106848_bib83","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18782","article-title":"Incidence, persistence, and remission rates of insomnia over 5 years","volume":"3","author":"Morin","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2025.106848_bib84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2025.106848_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945725005234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945725005234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:47:54Z","timestamp":1781880474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945725005234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":84,"alternative-id":["S1389945725005234"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2025.106848","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2025.106848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106848"}}